CD8A and neoplasm: Following antigen recognition by professional antigen presenting cells (APCs) or dendritic cells (DCs), major histocompatibility complex (MHC) proteins, both class I and II, present these processed antigens to activate tumor-specific CD8+ and CD4+ T cells, ultimately leading to tumor cell death.